The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, comprising, as an 
active ingredient, a 
fusion protein in which a tissue-penetrating 
peptide and an anti-
vascular endothelial growth factor (anti-VEGF) preparation are fused. More particularly, the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases, comprising, as an 
active ingredient, a 
fusion protein in which a tissue-penetrating 
peptide and an anti-VEGF preparation are fused; a method for prepraring an anti-VEGF preparation, which overcomes resistance and has an improved 
efficacy, the method comprising the steps of transforming a host 
cell with a recombinant vector comprising a 
nucleic acid sequence encoding a 
fusion protein in which a tissue-penetrating 
peptide and an anti-VEGF preparation are fused, culturing the 
cell, and recovering a fusion 
protein from the 
cell; a method for treating eye diseases, comprising administering an effective 
dose of the fusion 
protein according to the present invention to a subject in need thereof; and use of the fusion 
protein according to the present invention for preparing an agent for treating eye diseases. Compared to conventional anti-VEGF preparations, the composition according to the present invention is considered to have an improved 
efficacy and be able to be used for treating patients having 
drug resistance, by inhibiting various growth factors related to new blood vessels, besides VEGF, and by decreasing 
pericyte coverage. In addition, since 
drug delivery ability into the 
choroid tissue is improved when performing an intraocular injection, the composition can be developed as eye drops by reducing an administered dosage or extending an administration cycle, and by improving ocular penetrability.